TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Testosterone of less than 50 ng/dL~* Participants who was detected of disease progression on image or relapse of PSA (All PSA values measured 3 time at least one week interval are consecutively increased and final value is 2 ng/mL or more. If third value is not higher than second one, fourth measurement will be undertaken and its value must be higher than second one.)~* Participants who relapsed after CAB with bicalutamide~* Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1~* Aged 20 years or older~* Participants who provided written informed consent~Exclusion Criteria:~* Any prior treatment with enzalutamide, flutamide, abiraterone or chemotherapy, except for neoadjuvant therapy~* With active double cancer~* Any prior treatment with bicalutamide within 6 weeks~* Participants who received systemic biological therapy (except for existing approved drug for bone or treatment with luteinizing hormone-releasing hormone (LHRH) analogue) or received treatment with other antitumor agent for prostate cancer~* With serious complication~* History of hypersensitivity to enzalutamide or any other excipient of enzalutamide~* History of hypersensitivity to flutamide-containing agent~* With liver dysfunction~* Participants who are considered as inadequate by the investigator

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide (Type: EXPERIMENTAL): Enzalutamide 160 mg administered orally once a day as four 40-mg soft capsules
- Flutamide (Type: ACTIVE_COMPARATOR): Flutamide 125 mg administered orally three times a day as one tablet after meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age at entry 18-65~* Positive for Hepatitis C~* Nonresponder to previous treatment (minimum of 3 months) with an alpha Interferon plus ribavirin~* Liver biopsy demonstrating moderate to severe fibrosis or cirrhosis~Exclusion Criteria:~* Any cause for the liver disease other than chronic hepatitis C~* History or presence of complications of cirrhosis~* Alcohol or illicit drug use or methadone treatment within the past 2 years~* Treatment for chronic hepatitis C within the previous 6 months~* Diseases or conditions that could interfere with the subject's participation in and completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Overall study population (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 12 years of age~* Diagnosed with Acute Hepatic Porphyria (Acute Intermittent Porphyria, Hereditary Corproporhyria, Variegate Porphyria, aminolevulinic acid (ALA) dehydratase deficient porphyria)~* Elevated urinary or plasma porphobilinogen (PBG) or ALA values within the past year,~* Have active disease, with at least 2 documented porphyria attacks within the last 6 months~* Willing to discontinue or not initiate the use of prophylactic hemin throughout the study.~* Women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception~Exclusion Criteria:~* Clinically significant abnormal laboratory results~* Anticipated liver transplantation~* History of multiple drug allergies or intolerance to subcutaneous injections~* Active HIV, hepatitis C virus, or hepatitis B virus infection(s)~* History of recurrent pancreatitis

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Givosiran/Givosiran (Type: EXPERIMENTAL): Givosiran 2.5 mg/kg administered subcutaneously (SC), monthly (QM), for 6 months during the 6-Month Double-blind (DB) Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the Open-label Extension (OLE) Period.
- Placebo/Givosiran (Type: PLACEBO_COMPARATOR): Matching placebo (normal saline \[0.9% NaCl\]) was administered SC, QM, for 6 months during the 6-Month DB Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the OLE period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* the patients aged 20 to 79 years with primary hypercholesterolemia that was not sufficiently responsive to therapeutic lifestyle changes and had LDL-C level over 100 mg/dL in high risk group.~* Inclusion criteria was in accordance with drug treatment guidelines; coronary artery disease or equivalent group with LDL-C ≥100 mg/dl; patients with two or more risk factors and LDL-C≥130 mg/dl; patients with 0 or 1 risk factor and LDL-C \>160 mg/dl after therapeutic lifestyle changes~Exclusion Criteria:~* therapy with any other investigational drug within 30 days of randomization,~* history of hypersensitivity to HMG-CoA reductase inhibitors,~* uncontrolled hypertension,~* poorly controlled diabetes (glycosylated hemoglobin \[HbA1c\] \>9%),~* unstable angina or presented with new-onset myocardial infarction (within 6 months),~* creatinine \>2.5 mg/dl,~* alanine aminotransferase (ALT) \>2 x upper limit of normal (ULN), aspartate aminotransferase(AST) \>2 x ULN, or creatine kinase (CK) \>2 x ULN,~* history of malignancy or psychosis;~* chronic liver disease,~* drug or alcohol abuse, pregnancy, breastfeeding, failure to practice adequate contraception, cyclical hormonal contraceptives or intermittent use of hormone replacement therapies.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Lipinon-test formulation of atrovastain - 20mg (Type: EXPERIMENTAL): None
- Lipitor- branded formuation of atorvastatin-20mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects are non-immunocompromised males or females 18 years of age or older.~2. Subjects have ≥3% total body surface area plaque psoriasis.~3. Subjects are candidates for phototherapy or systemic therapy.~4. Subject must be diagnosed at least 6 months prior to entering the study.~5. Females must be surgically sterile, postmenopausal for \>5 years, or using a highly effective form of birth control (\<1% failure rate), for at least 30 days prior to test article exposure, with a negative serum pregnancy test.~Exclusion Criteria:~1. Subject is pregnant, lactating, or is planning to become pregnant during the study.~2. Subject is younger than 18 years of age.~3. Subjects with uncontrolled mental illness or active suicidal ideations based on baseline mental health questionnaire of choice.~4. Subject is known, or suspected of being unable to comply with the study protocol, in the opinion of the investigator.~5. Subject is currently enrolled in an investigational drug or device study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tildrakizumab 100 mg (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 2 to 75 years~* Subjects with primary humoral immunodeficiency, namely with a diagnosis of: CVID (Common Variable Immunodeficiency) as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) or XLA (X-linked Agammaglobulinemia)~* Written informed consent~Exclusion Criteria:~* Newly diagnosed PID~* Evidence of an active serious infection at the time of screening (i.e., but not limited to: bacteremia/septicemia, pneumonia, fungal osteomyelitis)~* Malignancies of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma and immunodeficiency with thymoma~* Known hyperprolinemia~* Hypoalbuminemia, protein-losing enteropathies, and any proteinuria~* Allergic reactions to immunoglobulins or other blood products~* Known antibodies to Immunoglobulin A (IgA)~* The subject is receiving steroids (oral and parenteral, daily ≥ 0.15 mg of prednisone equivalent/kg/day) or other systemic immunosuppressants~* Female who is pregnant, breast feeding or planning a pregnancy during the course of the study~* Participation in a study with an investigational product other than (IVIG) within 1 month prior to enrollment~* A positive result at screening on any of the following viral markers: Human Immunodeficiency Virus (HIV), Hepatitis C virus (HCV) and Hepatitis B virus (HBV)~* Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) concentration \> 2.5 times the upper normal limit (UNL)~* Creatinine concentration \> 1.5 times the UNL~* Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Type: EXPERIMENTAL): Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women~* History of regular menstrual cycles (21-42 days)~* Diagnosis of uterine fibroid(s)~* Abnormal vaginal bleeding associated with uterine fibroids~* Otherwise in good health~* Agrees to undergo surgery (hysterectomy) or any other invasive procedure if the study medication fails~* Negative pregnancy test~* Agrees to Double-barrier method of contraception~* Pap smear with no evidence of malignancy or pre-malignant changes~* Endometrial biopsy with no significant histological disorder~Exclusion Criteria:~* Any abnormal lab or procedure result the study-doctor considers important~* Severe reaction(s) to or are currently using any hormone therapy~* History of osteoporosis or other bone disease~* Previous myomectomy with 1 year and/or previous uterine artery embolization within 6 months~* History of Polycystic Ovary Syndrome or prolactinoma~* MRI shows significant gynecologic disorder~* Uterine size \> 25 weeks gestation~* Hemoglobin \< 8 g/dL at Day -1

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 6 years and \< 18 years~* History of physician diagnosed asthma~* Presenting to ED with breathing difficulty or cough~* Initial FEV1 25%-70% predicted~* Parent or guardian speaks English or Spanish.~Exclusion Criteria:~* Pediatric Asthma Score of 0~* Pregnancy or breast-feeding~* Immediate resuscitation required~* Chronic lung disease (other than asthma)~* Congenital heart disease~* Neuromuscular disease~* Suspected intrathoracic foreign body~* Allergy or other contraindication to study medication

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- T-piece Nebulizer (Type: ACTIVE_COMPARATOR): Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental T-piece Nebulizer (Hudson RCI® Micro Mist® nebulizer Teleflex Medical®, Research Triangle Park, NJ). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed.
- Breath-Enhanced Nebulizer (Type: EXPERIMENTAL): Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental Breath-Enhanced Nebulizer (NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer Salter Labs®, Arvin, CA). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local Collagen-Gentamicin and Extra Fixation of the Sternum for Prevention of Sternal Wound Infection in Cardiac Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All consecutive cardiac surgery patients operated via median sternotomy~Exclusion Criteria:~* Existing inclusion of the patient in another study of treatment aimed at reducing postoperative SWI.~* Known allergy or other contraindication to gentamicin or bovine collagen.~* Pregnancy or breast feeding~* Treatment with aminoglycosides during the last week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: ACTIVE_COMPARATOR): Use of local CollagenGentamicin and enhanced sternal fixation according to the Clinical routine introduced 4 years earlier as a result of a previous RCT on 2000 patients. In that sense these patients did not receive any intervention but just the standard treatment introduced 4 years earlier.~The aim of the study was to PROSPECTIVELY include a defined number of patients to compare their complication rate with that from aControl Group of patients från a previous RCT to verify that the effect of the treatment was stable over time.~As the study did not include any intervention compared to the present standard treatment at that time ethical approval was Exempt.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study~* history of premature ejaculation in the 6 months before study initiation not due to distress, interpersonal difficulty or medication withdrawal~* history of intravaginal ejaculatory latency time (IELT) of \< = 2 minutes in at least 3 out of 4 events~* blood pressure \< = 180/100 mmHg at screening and end of baseline~* patient and partner must agree to attempt sexual intercourse at minimum intervals specified in the protocol~* patient's partner must have a negative urine pregnancy test at time of screening~Exclusion Criteria:~* Not taken dapoxetine in a previous investigational drug study~* not using other forms of therapy for treatment of PE (behavioral therapy or medications applied to the skin)~* no history of any medical events that are associated with the development of PE~* not taken another investigational drug within 1 month~* no history of seizures or major psychiatric disorder such as depression or schizophrenia~* no alcohol abuse and dependence~* no known allergy or hypersensitivity to dapoxetine or other selective serotonin reuptake inhibitors (SSRIs)~* no partners with decreased interest in or painful intercourse or other forms of sexual dysfunction

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 20 or older, regardless of gender.~* Receiving stable maintenance hemodialysis 3 times a week.~* Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.~Exclusion Criteria:~* Patients having history of a pronounced brain / cardiovascular disorder.~* Patients having severe gastrointestinal disorders.~* Patients having severe hepatic disorders.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PA21 (Type: EXPERIMENTAL): None
- Sevelamer hydrochloride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged from 2 years to 65 years old~* Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of P. falciparum (or mixed with non-falciparum species)~* Asexual P. falciparum parasitaemia: 16 to 200,000/microlitre, determined on a thin or thick blood film~* Fever defined as \> 37.5°C tympanic temperature or a history of fever within the last 24 hours~* Written informed consent (by parent/guardian in case of children)~* Willingness and ability of the patients or parents/guardians to comply with the study protocol for the duration of the study~Exclusion Criteria:~* Signs of severe/complicated malaria~* Haematocrit \< 25% or Hb \< 8 g/dL at screening~* Acute illness other than malaria requiring treatment~* For females: pregnancy, breast feeding~* Patients who have received artemisinin or a derivative or an artemisinin-containing combination therapy (ACT) within the previous 7 days~* History of allergy or known contraindication to artemisinins, lumefantrine or amodiaquine~* Previous splenectomy~* corrected QT interval \> 450 milliseconds at moment of presentation~* Documented or claimed history of cardiac conduction problems~* Previous participation in the current study or another study in the previous 3 months

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ACT (Type: ACTIVE_COMPARATOR): Artemether-lumefantrine for 3 days plus primaquine at hour 24
- TACT (Type: EXPERIMENTAL): Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days plus primaquine at hour 24

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete